AAB Therapeutics develops precision biological drugs to treat cancer and autoimmune diseases without the systemic side-effects of chemotherapy. We are establishing a genetically programmable precision drug delivery platform that produces engineered extracellular vesicles (EVs). These nano-vesicles are decorated with antibodies to target them to specific cells and loaded with RNA drugs that kill the cancer cells. We use a proprietary AI model to choose the optimal combination of targeting antibodies. This modular platform can be rapidly re-targeted to other diseases by changing only a few components. Our initial focus is on liver and pancreatic cancer and autoimmunity, areas with significant unmet clinical need.

Registered in England and Wales as AAB Research Ltd. 

AAB Therapeutics

Org chart

Teams

Offices

AAB Therapeutics

Org chart

Teams

Offices

Related companies